Herpes Simplex Virus 1 UL36USP Antagonizes Type I Interferon-Mediated Antiviral Innate Immunity

被引:43
|
作者
Yuan, Hui [1 ,3 ]
You, Jia [2 ]
You, Hongjuan [4 ]
Zheng, Chunfu [1 ,5 ]
机构
[1] Fujian Med Univ, Sch Basic Med Sci, Dept Immunol, Fuzhou, Fujian, Peoples R China
[2] Fujian Med Univ, Affiliated Hosp 1, Fuzhou, Fujian, Peoples R China
[3] Jiangnan Univ, Peoples Hosp Wuxi 5, Ctr Clin Lab, Wuxi, Peoples R China
[4] Xuzhou Med Univ, Dept Pathogen Biol & Immunol, Jiangsu Key Lab Immun & Metab, Xuzhou, Jiangsu, Peoples R China
[5] Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada
关键词
HSV-1; UL36USP; IFNAR2; type I IFN-mediated signaling; HOST SHUTOFF PROTEIN; TEGUMENT PROTEIN; SIGNALING PATHWAY; ALPHA RECEPTOR; GENE; IFN; HERPES-SIMPLEX-VIRUS-1; DEGRADATION; CELLS; UL41;
D O I
10.1128/JVI.01161-18
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Type I interferons (IFNs), as major components of the innate immune system, play a vital role in host resistance to a variety of pathogens. Canonical signaling mediated by type I IFNs activates the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway through binding to the IFN-alpha/beta receptor (IFNAR), resulting in transcription of IFN-stimulated genes (ISGs). However, viruses have evolved multiple strategies to evade this process. Here, we report that herpes simplex virus 1 (HSV-1) ubiquitin-specific protease (UL36USP) abrogates the type I IFN-mediated signaling pathway independent of its deubiquitinase (DUB) activity. In this study, ectopically expressed UL36USP inhibited IFN-beta-induced activation of ISRE promoter and transcription of ISGs, and overexpression of UL36USP lacking DUB activity did not influence this effect. Furthermore, UL36USP was demonstrated to antagonize IFN-beta-induced activation of JAKs and STATs via specifically binding to the IFNAR2 subunit and blocking the interaction between JAK1 and IFNAR2. More importantly, knockdown of HSV-1 UL36USP restored the formation of JAK1-IFNAR2 complex. These findings underline the roles of UL36USP-IFNAR2 interaction in counteracting the type I IFN-mediated signaling pathway and reveal a novel evasion mechanism of antiviral innate immunity by HSV-1. IMPORTANCE Type I IFNs mediate transcription of numerous antiviral genes, creating a remarkable antiviral state in the host. Viruses have evolved various mechanisms to evade this response. Our results indicated that HSV-1 encodes a ubiquitin-specific protease (UL36USP) as an antagonist to subvert type I IFN-mediated signaling. UL36USP was identified to significantly inhibit IFN-beta-induced signaling independent of its deubiquitinase (DUB) activity. The underlying mechanism of UL36USP antagonizing type I IFN-mediated signaling was to specifically bind with IFNAR2 and disassociate JAK1 from IFNAR2. For the first time, we identify UL36USP as a crucial suppressor for HSV-1 to evade type I IFN-mediated signaling. Our findings also provide new insights into the innate immune evasion by HSV-1 and will facilitate our understanding of host-virus interplay.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression
    Negorev, Dmitri G.
    Vladimirova, Olga V.
    Ivanov, Alexey
    Rauscher, Frank, III
    Maul, Gerd G.
    JOURNAL OF VIROLOGY, 2006, 80 (16) : 8019 - 8029
  • [42] Duck Enteritis Virus VP16 Antagonizes IFN-β-Mediated Antiviral Innate Immunity
    Li, Yang
    Wang, Mingshu
    Cheng, Anchun
    Jia, Renyong
    Yang, Qiao
    Chen, Shun
    Zhu, Dekang
    Liu, Mafeng
    Zhao, Xinxin
    Zhang, Shaqiu
    Huang, Juan
    Ou, Xumin
    Mao, Sai
    Yu, Yanling
    Zhang, Ling
    Liu, Yunya
    Pan, Leichang
    Tian, Bin
    Rehman, Mujeeb Ur
    Chen, Xiaoyue
    JOURNAL OF IMMUNOLOGY RESEARCH, 2020, 2020
  • [43] West Nile Virus Noncoding Subgenomic RNA Contributes to Viral Evasion of the Type I Interferon-Mediated Antiviral Response
    Schuessler, Andrea
    Funk, Anneke
    Lazear, Helen M.
    Cooper, Daphne A.
    Torres, Shessy
    Daffis, Stephane
    Jha, Babal Kant
    Kumagai, Yutaro
    Takeuchi, Osamu
    Hertzog, Paul
    Silverman, Robert
    Akira, Shizuo
    Barton, David J.
    Diamond, Michael S.
    Khromykh, Alexander A.
    JOURNAL OF VIROLOGY, 2012, 86 (10) : 5708 - 5718
  • [44] Antiviral Activity of Oridonin Against Herpes Simplex Virus Type 1
    Jiang, Kai
    Feng, Jing
    Qi, Xia
    Ran, Lili
    Xie, Lixin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 4311 - 4323
  • [45] Antiviral effect of arginine against herpes simplex virus type 1
    Naito, Takeshi
    Irie, Hiroshi
    Tsujimoto, Kazuko
    Ikeda, Keiko
    Arakawa, Tsutomu
    Koyama, A. Hajime
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2009, 23 (04) : 495 - 499
  • [46] Post-translational modifications as a key mechanism for herpes simplex virus type I evasion of host innate immunity
    Zhang, Yongxing
    Xie, Junlei
    Feng, Ying
    Qadeer, Abdul
    Li, Shanni
    Deng, Xu
    Zhu, Lipeng
    Kong, Bo
    Xia, Zanxian
    FRONTIERS IN MICROBIOLOGY, 2025, 16
  • [47] Host Intrinsic and Innate Intracellular Immunity During Herpes Simplex Virus Type 1 (HSV-1) Infection
    Alandijany, Thamir
    FRONTIERS IN MICROBIOLOGY, 2019, 10
  • [48] Cellular nucleic acid-binding protein is essential for type I interferon-mediated immunity to RNA virus infection
    Chen, Yongzhi
    Lei, Xuqiu
    Jiang, Zhaozhao
    Fitzgerald, Katherine A.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (26)
  • [49] Luteolin inhibits herpes simplex virus 1 infection by activating cyclic guanosine monophosphate-adenosine monophosphate synthase-mediated antiviral innate immunity
    Wang, Yuan
    Li, Feng
    Wang, Zexu
    Song, Xiaowei
    Ren, Zhe
    Wang, Xiao
    Wang, Yifei
    Zheng, Kai
    PHYTOMEDICINE, 2023, 120
  • [50] Androstenediol antagonizes herpes simplex virus type 1-induced encephalitis through the augmentation of type I IFN production
    Daigle, J
    Carr, DJJ
    JOURNAL OF IMMUNOLOGY, 1998, 160 (06): : 3060 - 3066